-
公开(公告)号:EP3927823A1
公开(公告)日:2021-12-29
申请号:EP20759691.7
申请日:2020-02-22
发明人: NEMOTO Naoto , ANZAI Hironori , SUZUKI Takeru , KUMACHI Shigefumi , TERAI Takuya
-
2.
公开(公告)号:EP4442704A1
公开(公告)日:2024-10-09
申请号:EP22901376.8
申请日:2022-11-30
摘要: Provided are a peptide consisting of three complementarity determining regions and four framework regions, in which a framework 1 comprises an amino acid sequence represented by SEQ ID NO: 1, a framework 2 comprises an amino acid sequence represented by SEQ ID NO: 2, a framework 3 comprises an amino acid sequence represented by SEQ ID NO: 7, a framework 4 comprises an amino acid sequence represented by SEQ ID NO: 32, a complementarity determining region 1 is an amino acid sequence consisting of 10 amino acids, a complementarity determining region 2 is an amino acid sequence consisting of 16 or 17 amino acids, and a complementarity determining region 3 is an amino acid sequence consisting of 6, 12 or 15 amino acids; and a peptide library including the peptide.
-
公开(公告)号:EP3450554A1
公开(公告)日:2019-03-06
申请号:EP17775310.0
申请日:2017-03-29
摘要: The purpose of the present invention is to provide a high-speed in vitro screening method for any library selected from the group consisting of a cDNA display library and a nucleic acid aptamer library. This high-speed in vitro screening method involves: (i) a step for preparing positive spherical structures formed by immobilizing a target molecule on a spherical structure and negative spherical structures having no target molecules immobilized thereon; (ii) a step in which a target detection molecule, selected from the aforementioned library having a library size of greater than or equal to 10 10 , is bonded on each spherical structure to obtain spherical conjugates; (iii) a step in which the spherical conjugates are sorted into positive spherical conjugates and negative spherical conjugates with a cell sorter; (v) a step for supplying the nucleic acid on the surface of the sorted spherical conjugates for PCR; (vi) and a repetition step for repeating steps (ii) to (v) above using DNA obtained by PCR.
-
公开(公告)号:EP4299745A1
公开(公告)日:2024-01-03
申请号:EP22759586.5
申请日:2022-02-21
IPC分类号: C12N15/13 , A61K39/395 , A61P31/14 , A61P43/00 , C07K16/10 , C07K19/00 , G01N33/569
摘要: Provided is an antibody that binds to the N-protein of SARS-CoV-2, and a method for utilizing the antibody. An antibody that binds to SARS-CoV-2, having one or more structural domains comprising CDRs shown in the following (a) or (b): (a) CDR1 consisting of the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence, CDR2 consisting of the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 3 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence; or (b) CDR1 consisting of the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence, CDR2 consisting of the amino acid sequence of SEQ ID NO: 5 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence, and CDR3 consisting of the amino acid sequence of SEQ ID NO: 6 or an amino acid sequence obtained by substituting one amino acid with another amino acid in the amino acid sequence.
-
5.
公开(公告)号:EP4361175A1
公开(公告)日:2024-05-01
申请号:EP22828434.5
申请日:2022-06-21
发明人: KASHIWAGI Kenji , YANAGISAWA Teruhiko , YONEHARA Ryo , KUMACHI Shigefumi , NAKAO Kanako , TSUCHIYA Masayuki
摘要: A receptor tyrosine kinase agonist which is a single-domain antibody having a cell growth activity, and is at least one receptor tyrosine kinase agonist selected from the group consisting of a human fibroblast growth factor receptor 1 (FGFR1), a human fibroblast growth factor receptor 2 (FGFR2), a human fibroblast growth factor receptor 3 (FGFR3), and a human fibroblast growth factor receptor 4 (FGFR4).
-
公开(公告)号:EP4223878A1
公开(公告)日:2023-08-09
申请号:EP21875877.9
申请日:2021-10-01
发明人: MASAKI, Hidekazu , KUMACHI, Shigefumi , YONEHARA, Ryo , MATSUMURA, Yuta , KAWANO, Hibiki , TOJO, Takuto , MORIMOTO, Takuya , KATAYAMA, Kazuhiko , HAGA, Kei , TODAKA, Reiko , SAWADA, Akihito , TAKANO, Tomomi
IPC分类号: C12N15/13 , A61K39/215 , A61P31/14 , C07K16/10 , C07K16/46
摘要: A peptide which binds to SARS-CoV-2 and its usage are provided. The peptide which binds to SARS-CoV-2 comprises one or more structural domain comprising CDR3 consisting of an amino acid sequence of any of SEQ ID NOs: 1 to 9 or an amino acid sequence obtained by substituting at least one amino acid in the amino acid sequence with another amino acid.
-
7.
公开(公告)号:EP3919504A1
公开(公告)日:2021-12-08
申请号:EP19881718.1
申请日:2019-11-07
发明人: NEMOTO Naoto , UTSUGI Yasuhito
摘要: The purpose of the present invention is to provide a method for producing a peptide that interacts with a lipid bilayer, and a lipid-bilayer-penetrating peptide obtained through the method. Provided is a lipid-bilayer-penetrating peptide constructed from 10 to 100 amino acids, the peptide having an amino acid sequence that penetrates the lipid bilayer at the C-terminal, and having an amino acid sequence with at least six contiguous arginine at the N-terminal. Also provided is a construct for producing a lipid-bilayer-penetrating peptide, the construct including, from the 5' end toward the 3' end, a tag region 1, a region 1 for incorporating a fluorescent protein gene sequence, a fluorescent protein gene region, a region 2 for incorporating a fluorescent protein gene sequence, a random region, and a stop codon region, and the construct being such that the random region has the aforementioned sequences.
-
-
-
-
-
-